AstraZeneca Boosts Cancer Arsenal With 55% Acerta Pharma StakeMani
AstraZeneca said Thursday it would buy 55% of privately held biotech firm Acerta Pharma for $4 billion to bolster the UK pharmaceutical giant’s blood cancer treatment portfolio.
The latest deal caps an intense period of deal making for the UK drug maker as it races to refill its drug portfolio.
AstraZeneca unveils strategic transaction with Acerta Pharma
The latest deal envisages AstraZeneca paying an upfront payment of $2.5 billion for the stake and then a further unconditional $1.5 . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.